The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 2, 2011, Pages 205-213

  Cabrera, R ^a   Pannu, D S ^a   Caridi, J ^a   Firpi, R J ^a   Soldevila Pico, C ^a   Morelli, G ^a   Clark, V ^a   Suman, A ^a   George Jr , T J ^a   Nelson, D R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DOXORUBICIN; SORAFENIB; YTTRIUM 90;

ABDOMINAL PAIN; ADULT; AGE; AGED; ALOPECIA; ANOREXIA; ARTICLE; ASCITES; BRAIN DISEASE; CANCER PATIENT; CANCER STAGING; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CHOLECYSTITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HICCUP; HUMAN; HYDROTHORAX; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; LEG EDEMA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOW DRUG DOSE; MALE; NAUSEA; OVERALL SURVIVAL; PANCREATITIS; PRIORITY JOURNAL; SEX RATIO; SIDE EFFECT; SURVIVAL RATE; VARICOSIS; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; TREATMENT OUTCOME;

EID: 79959373568     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04697.x     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, Pisani P., Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-6. (Pubitemid 32911406)
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30. (Pubitemid 40310185)
3. Benvegnù L, Gios M, Boccato S, Alberti A,. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53: 744-9. (Pubitemid 38561455)
4. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-10. (Pubitemid 43980109)
5. El-Serag HB, Rudolph KL,. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76. (Pubitemid 46890874)
6. Veldt BJ, Chen W, Heathcote EJ, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-62. (Pubitemid 351945553)
7. Cabrera R, Nelson DR,. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 31: 461-76.
8. Llovet J, Burroughs AK, Bruix J,. Hepatocellular carcinoma. Lancet 2003; 362: 1901-7.
9. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Hepatology 2011; 53: 1020-2.
10. Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103: 914-21. (Pubitemid 351506379)
11. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-40.
12. Cabrera R, Caridi J, George T, et al. Safety of sorafenib alone or in combination with locoregional therapy in patients with advanced HCC and decompensated cirrhosis. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium. January 25, 2008 [Abstract 147].
13. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36. (Pubitemid 43112690)
14. Bruix J, Sherman M, LLovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30. (Pubitemid 32844200)
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
16. Lencioni R, Llovet JM,. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
17. Llovet J, Bruix J,. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42. (Pubitemid 36152543)
18. Llovet J, Ricci S, Mazzafero V, et al. Sorafenib versus placebo in advanced hepatocellular carcinoma. N Engl J 2008; 359: 378-90.
19. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
20. Llovet JM, Di Bisceglie AM, Bruix J, et al. Panel of experts in HCC-design clinical trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
21. Poggi G, Pozzi E, Tonini S, et al. Complications of Image guided transcatheter hepatic chemoembolisation of primary and secondary tuomours of the Liver. Anti Cancer Research 2010; 30: 5159-64.
22. Lammer J, et al. Prospective randomized study of doxorubicin-eluting-bead embolisations in the treatment of hepatocellular carcinoma: results of PRECISION V Study. Cardiovasc Intervent Radio 2010; 33: 41-52.
23. Lencioni R, Marrero J, Venook A, et al. Design and reationale for the tnon interventional global Investigation of therapeutic decisions in hepatocellular carcinoma and if uts treatment with sorafenib (GIDEON) study. Int J Clin Pract, 2010; 64: 1034-41.
24. Chaparro M, González Moreno L, Trapero-Marugán M, et al. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther 2008; 28: 1269-77.
25. Huang YH, Wu JC, Chen SC, et al. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther 2006; 23: 129-35.